Genfit (NASDAQ:GNFT - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $13.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 114.52% from the company's previous close.
Genfit Stock Up 9.4 %
NASDAQ:GNFT traded up $0.52 during mid-day trading on Friday, hitting $6.06. 108,904 shares of the company's stock traded hands, compared to its average volume of 17,189. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. The firm's 50 day simple moving average is $4.54 and its 200 day simple moving average is $4.23. Genfit has a 1 year low of $2.97 and a 1 year high of $6.08.
Genfit Company Profile
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
